



Loramyc® obtains Marketing Authorization in Switzerland

Paris, August 24, 2009 – BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that Loramyc® has obtained Marketing Authorization in Switzerland for the treatment of oropharyngeal candidiasis in immunocompromised patients (mainly cancer and AIDS patients with oral opportunistic infections).

“This approval represents an important milestone for Loramyc® which is now registered in 12 countries in Europe, including Switzerland. This step will thus reinforce Loramyc® opportunity for a European commercial agreement for which we are actively seeking a suitable partner involved in the supportive care field”, said Dominique Costantini, President and CEO of BioAlliance Pharma.

“Loramyc® value has also recently been strengthened by the US FDA acceptance of its New Drug Application”, added Dominique Costantini.

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. For more information, visit the BioAlliance Pharma web site at <http://www.bioalliancepharma.com>.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma S.A.'s website (<http://www.bioalliancepharma.com>).

BioAlliance Pharma SA

Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com